Volume 6.46 | Dec 4

Prostate Cell News 6.46 December 4, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Study Identifies Potential Therapeutic Targets for Metastatic Prostate Cancer
Scientists have pinpointed five specific enzymes called protein kinases that play a role when prostate cancer spreads to bone. The discovery could point the way toward new drugs that slow or stop prostate cancer from spreading. [Press release from the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research discussing online prepublication in Proceedings of the National Academy of Sciences]
Press Release | Abstract | Full Article
Development of Simplified and Defined Cell Culture for hPSCs - Watch Now!
PUBLICATIONS (Ranked by impact factor of the journal)

The Pepper’s Natural Ingredient Capsaicin Induces Autophagy Blockage in Prostate Cancer Cells
Investigators showed that capsaicin induced prostate cancer cell death in a time- and concentration-dependent manner, increased the levels of microtubule-associated protein light chain 3-II and the accumulation of the cargo protein p62 suggesting an autophagy blockage. [Oncotarget] Full Article

NES1/KLK10 Gene Represses Proliferation, Enhances Apoptosis and Down-Regulates Glucose Metabolism of PC3 Prostate Cancer Cells
Given that the androgen-independent growth characteristic of the PC3 cell line is more similar to clinical castration-resistant prostate cancer, researchers studied the role of KLK10 in PC3. In vitro and in vivo assays showed that over-expressing KLK10 in PC3 could decelerate tumor proliferation, which was accompanied with an increase in apoptosis and suppression of glucose metabolism. [Sci Rep] Full Article

An In Vitro System to Characterize Prostate Cancer Progression Identified Signaling Required for Self-Renewal
Scientists developed an in vitro model to help identify RB– and PTEN-loss signatures during the malignant progression of prostate cancers. They found that deletion of Rb, Pten or both stimulated prostasphere formation and tumor development in immune-compromised mice. [Mol Carcinog] Abstract

A Selective Alpha1D-Adrenoreceptor Antagonist Inhibits Human Prostate Cancer Cell Proliferation and Motility In Vitro
The authors investigated the in vitro antitumor action of A175, a selective alpha1D-AR antagonist recently obtained by modifying the potent, but not subtype-selective alpha1-AR antagonist (S)-WB4101, in the hormone-refractory PC3 and DU145 PC cell lines. [Pharmacol Res] Abstract

KPT-330, a Potent and Selective Exportin-1 (XPO-1) Inhibitor, Shows Antitumor Effects Modulating the Expression of Cyclin D1 and Surviving in Prostate Cancer Models
Scientists investigated the effects of a new class of selective inhibitor of nuclear export compounds in models of prostate cancer. They evaluated the expression of XPO-1 in human prostate cancer tissues and cell lines. [BMC Cancer] Full Article

Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells
Treatment of different prostate cancer cells with curcumin or α-tomatine alone resulted in growth inhibition and apoptosis in a concentration-dependent manner. Combinations of α-tomatine and curcumin synergistically inhibited the growth and induced apoptosis in prostate cancer PC-3 cells. [PLoS One] Full Article

Messenger RNA Profile Analysis Deciphers New Esrrb Responsive Genes in Prostate Cancer Cells
Scientists investigated the mRNA profile alterations induced by estrogen related receptor β (Esrrb) expression and its synthetic ligand DY131 in human prostate cancer DU145 cells via RNA-Seq analysis. [BMC Mol Biol] Full Article

Lysyl Oxidase Propeptide Stimulates Osteoblast and Osteoclast Differentiation and Enhances PC3 and DU145 Prostate Cancer Cell Effects on Bone In Vivo
Effects of overexpression of rLOX-PP in DU145 and PC3 prostate cancer cell lines on bone structure in vivo after intramedullary injections were determined. The authors showed that prostate cancer cell conditioned media inhibited osteoblast differentiation in bone marrow-derived cells, which was reversed by rLOX-PP treatment.
[J Cell Commun Signal]


Androgen Deprivation Therapy (ADT) Plus Docetaxel versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-Term Survival Analysis of the Randomized Phase III GETUG-AFU15 Trial
Survival benefits of docetaxel added to ADT were shown in the CHAARTED trial in patients with metastatic high-volume disease. The authors assessed the impact of metastatic burden and updated overall survival data of the GETUG-AFU15 study. [Eur Urol] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Virus Encoded Circulatory miRNAs for Early Detection of Prostate Cancer
The authors provide a short review on miRNAs, virus infection and viral encoded miRNAs in prostate cancer (PCa), with a primary focus on circulating miRNAs as potential non-invasive biomarkers for PCa patients. [BMC Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
New EU Project Designed to Link Diagnosis and Treatment of Diseases over the Long Term
An international team from four EU countries plans to use an innovative concept to improve the use of companion diagnostics in disease and develop new approaches to therapy in the long term. [Johannes Gutenberg-Universität Mainz] Press Release

Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide. [University of Montreal] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cancer as an Evolving and Systemic Disease
March 12-15, 2016
New York City, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Positions – Prostate Cancer (Baylor College of Medicine)

Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute)

Postdoctoral Position – Molecular Cancer Biology (University of Pennsylvania)

Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Postdoctoral Position – Androgen Response in Prostate Cancer (University of Victoria)

Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us